Roger Montgomery on Sirtex, page-79

I’m not sure the results are confusing at all. Or as difficult as Roger makes out.

SRX stated categorically on a number of occasions that if the primary end-point of PFS was not met then first line SIRT has a weak case and would remain a salvage therapy.

The primary outcome was not met ... full stop.

Next there are 7 secondary outcomes. SRX announce a statistically sig improvement on one of these outcomes - PFS in the liver.

So what? It is simply a surrogate for OS. In the 2010 study SIRSPHERES failed to beat placebo on OS. If OS were showing a positive trend you can bet SRX would have mentioned it.

Plan A was to present only the top line overall PFS results in this announcement. Plan B emerges from the failure. But in the absence of positive OS data it is doomed to fail.

The truth is just as the company stated before the results.